CNS Drugs from Fungal Genetics Research






- Luminous Mind Inc. (LMI) is dedicated to developing superior and differentiated treatments for Central Nervous System disorders, including depression, PTSD, pain, anxiety, and addiction
- Although a few companies are involved in mushroom genetics research, LMI is the only company totally focused on the treatment of CNS disorders
- The establishment of our Fungal Genetics Research Program in Oregon will help LMI to pursue the enormous untapped potential in mushrooms, fungi and endophytes for drug and patented nutraceutical development

Fungi have an unparalleled record in drug discoveries






LMI's Research Activity on Genomes of Fungi



NOW	SOON	GOAL	
Psilocybe mushrooms for therapeutic use in Oregon			
	Psilocybe entourage metabolites for therapy		
Mushroom nutraceutical antioxidants, cholesterol lowering sterols			
	Neurosteroids for drug leads		
		Clinical trials	
Bioinformatic discovery of novel biosynthetic gene clusters			
	Genetic crosses for nutrient optimization		

LMI's pipeline, built on a fungal drug discovery platform





LMI Mycologists & Geneticists

LMI's Industry Leading Team of "drug hunting scientists"





Proven entrepreneur across academia. finance, and industry. Co-founded, financed or led biotech companies with an aggregate value of +\$15B.

LOUIS HERLANDS, PHD CEO / CO-FOUNDER




As the former editor of Nature Genetics for 15 years, he set new standards for research in agricultural genomics and for genetics of common and rare diseases.


MYLES AXTON, PHD **GENETICS RESEARCHER**



drug discovery.



MICHAEL MAKI FTHNOBOTANY - THE SCHULTES CENTER



ALAN JACOBSON. PHD. MBA MEDICINAL CHEMISTRY

30+ years developing better therapeutics for the nervous system and other areas. 8 drugs to the clinic, 2 marketed drugs, over \$2B in sales for Cephalon (Teva) & Cubist (Merck)..

Director of the Richard Evans Schultes

Center for Amazonian Ethnobotanical

Certification. Over 35 years' experience

in renewable agriculture, mycology and

Research. Pioneer in organic crop

agroforestry.

MARCIE GLICKSMAN. PHD CSO CONSULTANT





DAVID THALER, PHD GENETICS



DAVID BORSOOK PHD, MD BRAIN SYSTEMS BIOLOGY



MB, CHB, PHD **NEUROLOGY, BIOTECH** Practicing physician with a PhD in functional neural imaging, and consultant on corporate finance strategy for pharmaceuticals. Entrepreneur and inventor.


Genetics and microbiology; transdisciplinary scientist. Molecular biology, cognitive

psychology & harm reduction. Associate. Prof., Rockefeller. University of Basel, Biozentrum

DAVID BLEAKMAN. PHD PHARMACOLOGY NEUROSCIENCE

LMI's diverse, agile Three-Part Strategy





- In-licensing, repurposing and traditional medicine opportunities pursued for neural and psychiatric disorders to drive valuation
- The psychoactive agents of these plants, endophytes and fungi are isolated and characterized, both chemically and pharmacologically, and used as leads in our drug discovery programs.
- LMI is building a pipeline to include NCEs based on bioactives that have CNS, brain plasticity, and anti-inflammatory activities.

Genomic discovery in fungi and endophytes - A huge new field



Company	Round	Funding	Strategy
LifeMine Therapeutics	С	\$295m	Fungal genomics, AI, Synthetic biology
Hexagon Bio	В	\$116.3m	Fungal products against cancer and infection. Database of metabolites and protein targets.
21 st .BIO	VC series	EU86m	Expression in fungi, yeast, bacteria. Novozyme technology for expression and testing natural molecules at scale
Indigo Ag	F	\$1.2bn	Crop protection. Identified culture mixes that promote seed germination and plant pathogen resistance

LMI will bring these discoveries into CNS therapy

Fungal Genetics Research Program



For more information or to schedule a presentation please contact:

Myles Axton, PhD Chief Genetics Researcher P: 800-816-9630 x705 M: 845-806-1261 <u>MAxton@LuminousMindInc.com</u>



How: Genetics and biochemical genetics of *Psilocybe cubensis* and other mushrooms. LMI uniquely skilled and positioned.

Where: Immediately establish lab in Oregon with the legalization of *Psilocybe* therapy and its related mushroom communities.

When: Time critical. Potential competitors waking up. Rapid high quality work to establish LMI as pioneer.

Amount: Target of \$1-\$3 million. Special Investment Offering in <u>Luminous</u> <u>Mind Inc.</u> via a <u>Convertible Promissory Note.</u> Minimum investment \$50K.